Telomerase inhibitors for use in therapy

A telomerase inhibitor and inhibitor technology, which can be used in the treatment of inflammatory diseases and cancer, and can solve problems such as unknown NFκB activity

Inactive Publication Date: 2015-07-22
AGENCY FOR SCI TECH & RES
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Uncontrolled activation of NFκB and its effects, such as chronic inflammation, are hallmarks o...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Telomerase inhibitors for use in therapy
  • Telomerase inhibitors for use in therapy
  • Telomerase inhibitors for use in therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0206] Non-limiting examples of the present invention, including the best mode and comparative examples, will be further described in more detail by referring to specific examples, which should not be construed as limiting the scope of the present invention in any way.

[0207] method

[0208] Cells and Reagents

[0209] Wild type (WT), mTerc – / – 、mTERT – / – , MEF, via mTerc + / - or mTERT + / - Breeding pairs were timed mated to obtain, as previously described 15,36,37,39,42 . Briefly, embryos were harvested at E13.5, internal organs removed, and incubated at 37°C in 10% CO 2 Fibroblasts were cultured in Duchenne's Modified Eagle's Medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2mM L-glutamine, 2mM sodium pyruvate, 2% β-mercaptoethanol and 1X PSF (penicillin, streptomycin and amphotericin). HeLa, 293T, MDA-MB-231 and MEF at 37°C in 5% CO 2 Cultured in Duchenne's Modified Eagle's Medium (DMEM); A2780cp and MCF7 cells were cultured in RPMI;...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to methods of treating an inflammatory disease and/or cancer in a patient in need thereof, the method comprising administering a telomerase inhibitor to the patient.

Description

technical field [0001] The present invention generally relates to methods of treating inflammatory diseases and cancer. Background of the invention [0002] Telomeres are (TTAGGG) n A tandem repeat of a sequence at the end of a chromosome to which a protein complex known as the "shelterin complex" binds. This complex is thought to protect telomeres from degradation and has DNA repair activity 1,2 . Telomere length is maintained and replenished by the riboproteinase 'telomerase' 3,4 . Accumulating evidence suggests that mature telomerase 5-10 and masking complex members 11-14 are also involved in non-canonical activities at extratelomere sites or organelles 5,13,15-19 . [0003] Chromosome ends are elongated by telomerase 20 Prevents aging and allows cells to overcome the Hayflick limit 21 . In 80-90% of all cancers 22 and some other human diseases besides cancer 5,23,24 , telomerase is reactivated. Although telomere elongation is postulated to be a major functi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/167A61K48/00A61P35/00A61P29/00
CPCC12N15/1137A61K31/167C12Y207/07049A61K31/343C12N2310/14A61K31/7105A61K31/713A61P29/00A61P35/00A61K39/3955C07K16/40C07K2317/76C12N2320/30
Inventor 维奈·特高卡尔
Owner AGENCY FOR SCI TECH & RES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products